MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Pacific Biosciences of California Inc

Закрыт

СекторЗдравоохранение

2.21 -4.33

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.21

Макс.

2.39

Ключевые показатели

By Trading Economics

Доход

3.9M

-38M

Продажи

-1.3M

38M

Рентабельность продаж

-98.853

Сотрудники

575

EBITDA

3.2M

-32M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+2.13% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

12 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-66M

607M

Предыдущая цена открытия

6.54

Предыдущая цена закрытия

2.21

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

Pacific Biosciences of California Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

16 янв. 2026 г., 23:29 UTC

Популярные акции

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 янв. 2026 г., 22:48 UTC

Приобретения, слияния, поглощения

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 янв. 2026 г., 22:43 UTC

Приобретения, слияния, поглощения

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 янв. 2026 г., 22:22 UTC

Приобретения, слияния, поглощения

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Tech, Media & Telecom Roundup: Market Talk

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Auto & Transport Roundup: Market Talk

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

16 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

16 янв. 2026 г., 21:48 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 янв. 2026 г., 21:41 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 янв. 2026 г., 21:38 UTC

Приобретения, слияния, поглощения

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 янв. 2026 г., 21:30 UTC

Приобретения, слияния, поглощения

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 янв. 2026 г., 20:44 UTC

Отчет

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 янв. 2026 г., 20:42 UTC

Обсуждения рынка

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 янв. 2026 г., 20:28 UTC

Обсуждения рынка

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 янв. 2026 г., 19:12 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 янв. 2026 г., 18:53 UTC

Обсуждения рынка

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 янв. 2026 г., 18:41 UTC

Обсуждения рынка

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 янв. 2026 г., 18:31 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 янв. 2026 г., 17:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

16 янв. 2026 г., 17:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

16 янв. 2026 г., 17:20 UTC

Обсуждения рынка

Health Care Roundup: Market Talk

16 янв. 2026 г., 17:03 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

16 янв. 2026 г., 17:03 UTC

Обсуждения рынка

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 янв. 2026 г., 16:32 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 янв. 2026 г., 16:20 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

Сравнение c конкурентами

Изменение цены

Pacific Biosciences of California Inc Прогноз

Целевая цена

By TipRanks

2.13% рост

Прогноз на 12 месяцев

Средняя 2.4 USD  2.13%

Максимум 3 USD

Минимум 2 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Pacific Biosciences of California Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

5 ratings

3

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

1.13 / N/AПоддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat